Patient Safety Awareness Week: 52 Weeks a Year

03.07.14 | By

A patient should never have to worry about the safety of their medicines. Unfortunately, patient’s lives are put at risk across the country due to counterfeit, substandard, or otherwise unsafe medicines.

Conversations: Part D Protected Classes

03.06.14 | By

Since taking effect in 2006, Medicare Part D has provided seniors with critical access to the prescription medications they need. As part of the program, patients have broader access to medicines that fall into one of six “protected classes” that include anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals and immunosuppressants.

Changing the Dynamic of Biopharmaceutical Research Starts with Collaboration

03.05.14 | By

Patients, physicians, biopharmaceutical companies, and the federal government all want the same thing: New treatment options to save lives from diseases that claim far too many.

Tune in Tomorrow: Sunshine Act on CBS This Morning

03.03.14 | By

CBS This MorningThe Sunshine Act encourages transparency around the interactions between physicians and biopharmaceutical professionals. These conversations are vital to improving patient care.

Week in Review: R&D Fueled By Collaboration

02.28.14 | By

We revisit the research and development (R&D) pipeline quite a bit, because it is a crucially important aspect of modern medicine. Having recently released our Medicines in Development report on the 180 medicines in the pipeline to treat diabetes and related conditions, it is important to recognize the steps that fuel innovation and medical advances.

‘Medicines in Development’ just part of equation to treat diabetes

02.27.14 | By

By 2020, nearly half of all Americans will have at least one chronic condition. As more and more people are afflicted by chronic disease, it is increasingly important to develop new ways to prevent, manage, and treat these life-altering conditions.

Collaborating for Future Progress

02.26.14 | By

The existing model of bringing new medicines to patients is a costly, exhaustive, and thorough process. In fact, to develop a new medicine under the federal process takes about $1 billion and 10 years — with a failure rate of roughly 99 percent.

Intellectual Property Rights Are Crucial to Protect Global Patient Health

02.24.14 | By

Today, I had the opportunity to offer PhRMA’s perspective on inadequate intellectual property (IP) rights and other major trade barriers around the world during the U.S. Trade Representative’s (USTR) public hearing in the 2014 Special 301 Review process.

Peter Huber Explains How 20th Century Law is Undermining 21st Century Medicine

02.20.14 | By

A new book, the Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine, provides a fascinating overview of advances in biomedical science with the potential to revolutionize how diseases are treated by providing patients with more targeted therapies.

PhRMA Statement on Proposed Rule on Medicare Advantage & Part D

Washington, D.C. (February 19, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement:

“PhRMA opposes the proposed rule on Medicare Advantage and Part D that CMS released in early January because it could disrupt care for millions of beneficiaries. The Part D program is already working well, making the proposed rule unnecessary and harmful. Quite simply, it is a solution in search of a problem.

Pages

Subscribe to RSS - Opinion